Key result
Periostin peptide improves EF and reduces infarct size ~22% in porcine MI models despite increased fibrosis.
Why the study?
Does recombinant periostin peptide improve cardiac function and reduce infarct size in a swine model of myocardial infarction?
Does recombinant periostin peptide improve cardiac function and reduce infarct size in a swine model of myocardial infarction?
While periostin peptide improves cardiac function and reduces infarct size post-MI in a large animal model, its clinical translation is hindered by the induction of remote myocardial fibrosis.
Answers are grounded in this paper and cite their sources.
Periostin peptide warrants caution in MI models due to fibrosis; leaves open therapeutic potential pending fibrosis mitigation.
AIMS: Mammalian myocardium has a finite but limited capacity to regenerate. Experimentally stimulating proliferation of cardiomyocytes with extracellular regeneration factors like periostin enhances cardiac repair in rodents. The aim of this study was to develop a safe method for delivering regeneration factors to the heart and to test the functional and structural effects of periostin peptide treatment in a large animal model of myocardial infarction (MI). METHODS AND RESULTS: We developed a controlled release system to deliver recombinant periostin peptide into the pericardial space. A single application of this method was performed two days after experimental MI in swine. Animals were randomly assigned to receive either saline or periostin peptide. Experimental groups were compared at baseline, day 2, 1 month and 3 months. Treatment with periostin peptide increased the EF from 31% to 41% and decreased by 22% the infarct size within 12 weeks. Periostin peptide-treated animals had newly formed myocardium strips within the infarct scar, leading to locally improved myocardial function. In addition the capillary density was increased in animals receiving periostin. However, periostin peptide treatment increased myocardial fibrosis in the remote region at one week and 12 weeks post-treatment. CONCLUSION: Our study shows that myocardial regeneration through targeted peptides is possible. However, in the case of periostin the effects on cardiac fibrosis may limit its clinical application as a viable therapeutic strategy.
No takes yet. Share an insight, caveat, or question.
Ladage et al. (2013) studied Myocardial Infarction (n=13). Periostin peptide in gelfoam vs. Control gelfoam with buffer was evaluated on Ejection Fraction (EF) at 3 months (p=<0.05). Periostin peptide treatment increased ejection fraction from 31.4% to 40.7% and decreased infarct size by 22% over 12 weeks in a porcine model of myocardial infarction, but increased myocardial fibrosis.
Synapse has enriched 10 related papers. Consider them for comparative context: